TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Intervention completion rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean initial bond strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative cylindrical error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of peritonitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Technique failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of HIV tested
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting and submaximal RPPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of hospitalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to oral intake restart
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Cys levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean E(h) Cys
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: proportion of women worried by treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: compliance with medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Level of Il‐17A in EBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of Il‐23 in EBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum calcium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tidal volume during pressure-controlled ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severe visual acuity loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of children meeting PA guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average minutes spent in MVPA per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time spent being sedentary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with surgical decision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clarity about surgical options
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prostate-Specific Antigen (PSA) response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical benefit
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in secondary prevention components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence rate of pressure injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Walking Distance (WD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful intubation attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of FT‐LMA insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events during and after intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Post-HF all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Pain score after analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ejection fraction change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BALF-IL-12 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke rate within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Transient ischemic attacks linked to CEA
Endpoint domain: Adverse events/effects
Primary endpoint: Myocardial infarctions linked to CEA
Endpoint domain: Adverse events/effects
Primary endpoint: mortality after 3 months
Endpoint domain: Mortality/survival
Primary endpoint: independence at home
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Frequency of dress changing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in signs and symptoms of chronic blepharitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal reflux oesophagitis healing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: wound area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: closure rate of venous leg ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic relapse/recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with pain control
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: requirement for supplemental analgesia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Composite outcome of CMV disease, invasive bacterial or fungal disease, or death
Endpoint domain: Mortality/survival
Primary endpoint: 1-log10 reduction in HIV-1 load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in CD4+ cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of angiospasm
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of vagal reflex
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in hyperemic stenosis resistance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: necrotic-core area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: average intensity of pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pressure, heaviness and fullness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patients described as much or very much improved
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: success rate of usability tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preference for interactive visual displays
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ADL problems identified
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of CAD events
Endpoint domain: Mortality/survival
Primary endpoint: percentage of pain-free cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of days with pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of days with moderate or severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CCA-IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: C-reactive protein level normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilation increase during normoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ventilatory response at fifth minute of isocapnic hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sympathetic response to apnoea after hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of early posttraumatic seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: VAS scores during IUD insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction by the end of insertion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: oral bioavailability of S-ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clearance of S-ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: norketamine AUC at steady state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A1C level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Perceived cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean percent change from baseline in lumbar spine bone mineral density (BMD) at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impaired school performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of blood eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Polyp scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urate-lowering efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TBR residuals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of medication taken
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Severity of dyspeptic symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NOS-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COX-2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative narcotic analgesia use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: development of urinary retention
Endpoint domain: Adverse events/effects
Primary endpoint: Time to recontamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of EUS in diagnosing venous invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: specificity of EUS in diagnosing venous invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: immediate memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: delayed memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Firmicutes/Bacteroidetes ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faecalibacterium abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma levels of glucagon‐like peptide 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of cystoid macular edema (CME)
Endpoint domain: Adverse events/effects
Primary endpoint: mean shear bond strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ziprasidone AUC(0,infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Cmax of ziprasidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of celecoxib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve to infinity (AUC∞) of celecoxib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgery-related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture risk assessment accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone formation levels (BSAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone resorption levels (NTx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SpO2 reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in symptoms of OA of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of corneal infiltrative events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of contact lens papillary conjunctivitis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of neovascularization and corneal wrinkling
Endpoint domain: Adverse events/effects
Primary endpoint: Constipation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sexual-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Activities of daily living
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Langerhans cell density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fall incidence ratio
Endpoint domain: Mortality/survival
Primary endpoint: functional cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alanine aminotransferase flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔFEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ΔQaw
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Initiation of long-term dialysis therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in periorbital wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in perioral wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: disability scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cellularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Flare
Endpoint domain: Adverse events/effects
Primary endpoint: Total number of allogeneic red cell transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma [Hb]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: RBC [Hb]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Functional recovery improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MEP amplitude increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Erythema score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Oedema score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Endothelial cell morphology changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PONV rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative morphine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: d6‐α‐tocopherol absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma d6‐α‐tocopherol AUC from 0 to 72 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximal concentrations (Cmax) of d6‐α‐tocopherol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: NA and VL decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed psychomotor development at one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean IOP reduction at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: physicians' assessment of patient tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color discriminating sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suppression of UVB light‐induced erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence and severity of telangiectasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of serum cortisol level suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Achieved hemostasis at 4 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Achieved hemostasis at 10 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Retracement of maxillary anterior teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement of first molars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental alveolar bone remolding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episcleral venous pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: tobacco abstinence (7-day point prevalence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS pain on the first day after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BFI total score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: LASA QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: adapted SSQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FEV(1) and FEV(1)/FVC values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: OSDI values improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of new intracerebral hematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Improvement in urgency symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients able to finish tasks before voiding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived benefit with tolterodine ER
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in performance level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: random blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insomnia Severity Index (ISI) score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Hospital Anxiety and Depression Scale (HADS) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HADS subscale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cotinine-confirmed quit rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of abnormal clones in leukemic karyotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical response rate at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mortality prediction based on HRCT extent
Endpoint domain: Mortality/survival
Primary endpoint: Root mean square (RMS) of total higher‐order aberrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-contrast uncorrected visual acuity and best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median complication-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Awake PaO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oxygen savings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C5aR1 mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: C5aR2 mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean CT number of the pancreas (HUpancreas)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor-to-pancreas contrast (HUtumor-to-pancreas)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: children's MVPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of 5-HT+C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes